ECSP099251A - Formulaciones farmacéuticas - Google Patents
Formulaciones farmacéuticasInfo
- Publication number
- ECSP099251A ECSP099251A EC2009009251A ECSP099251A ECSP099251A EC SP099251 A ECSP099251 A EC SP099251A EC 2009009251 A EC2009009251 A EC 2009009251A EC SP099251 A ECSP099251 A EC SP099251A EC SP099251 A ECSP099251 A EC SP099251A
- Authority
- EC
- Ecuador
- Prior art keywords
- pharmaceutical formulations
- active agent
- formulation
- release
- salt
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 239000013543 active substance Substances 0.000 abstract 2
- 238000009472 formulation Methods 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 239000012738 dissolution medium Substances 0.000 abstract 1
- MQOBSOSZFYZQOK-UHFFFAOYSA-N fenofibric acid Chemical compound C1=CC(OC(C)(C)C(O)=O)=CC=C1C(=O)C1=CC=C(Cl)C=C1 MQOBSOSZFYZQOK-UHFFFAOYSA-N 0.000 abstract 1
- 229960000701 fenofibric acid Drugs 0.000 abstract 1
- 229920001477 hydrophilic polymer Polymers 0.000 abstract 1
- 238000000338 in vitro Methods 0.000 abstract 1
- 239000011159 matrix material Substances 0.000 abstract 1
- 150000003839 salts Chemical group 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
- A61K9/2846—Poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
La presente invención proporciona una formulación de liberación modificada que comprende un agente activo en una matriz de polímero hidrofílico en donde el agente activo es una sal de ácido fenofíbrico en donde la velocidad de liberación de la formulación en una disolución in vitro es considerablemente independiente de la fuerza iónica de los medios de disolución.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US82925506P | 2006-10-12 | 2006-10-12 |
Publications (1)
Publication Number | Publication Date |
---|---|
ECSP099251A true ECSP099251A (es) | 2009-06-30 |
Family
ID=38961056
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EC2009009251A ECSP099251A (es) | 2006-10-12 | 2009-04-13 | Formulaciones farmacéuticas |
Country Status (14)
Country | Link |
---|---|
EP (1) | EP2081563A1 (es) |
JP (1) | JP2010506855A (es) |
KR (1) | KR20090119959A (es) |
CN (1) | CN101677981A (es) |
AU (1) | AU2007307641A1 (es) |
CA (1) | CA2672686A1 (es) |
CO (1) | CO6160302A2 (es) |
EA (1) | EA200900531A1 (es) |
EC (1) | ECSP099251A (es) |
IL (1) | IL198160A0 (es) |
MX (1) | MX2009003815A (es) |
SG (1) | SG175570A1 (es) |
WO (1) | WO2008046052A1 (es) |
ZA (1) | ZA200902488B (es) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2285357B8 (en) * | 2008-05-30 | 2014-07-23 | UCB Pharma, S.A. | Pharmaceutical compositions comprising brivaracetam |
CN102304103A (zh) * | 2011-06-03 | 2012-01-04 | 郑州泰基鸿诺药物科技有限公司 | 一种非诺贝特酸盐、制备方法、药物组合物及应用 |
CN102659570B (zh) * | 2012-05-17 | 2014-05-28 | 安润医药科技(苏州)有限公司 | 二氟非诺贝特酸及其在药学上可接受的盐,以及它们的制备方法和应用 |
FR3050112B1 (fr) * | 2016-04-15 | 2020-09-04 | Soc Civ Immobiliere Gecinq | Utilisation de l'acide fenofibrique dans le traitement des maladies hepatiques |
CN107496397A (zh) * | 2016-06-14 | 2017-12-22 | 重庆安格龙翔医药科技有限公司 | 一种二甲双胍与非诺贝酸的复合物及其制剂 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7259186B2 (en) * | 2002-12-17 | 2007-08-21 | Abbott Laboratories | Salts of fenofibric acid and pharmaceutical formulations thereof |
EP1832285A1 (en) * | 2002-12-17 | 2007-09-12 | Abbott GmbH & Co. KG | Formulation comprising fenofibric acid or a physiologically acceptable salt thereof |
RU2356549C2 (ru) * | 2002-12-17 | 2009-05-27 | Эббетт ГмбХ унд Ко.КГ | Композиция, включающая фенофибриновую кислоту, ее физиологически приемлемую соль или производное |
EP1559419A1 (en) * | 2004-01-23 | 2005-08-03 | Fournier Laboratories Ireland Limited | Pharmaceutical formulations comprising metformin and a fibrate, and processes for their obtention |
EP1868587A2 (en) * | 2005-04-08 | 2007-12-26 | Abbott Laboratories | Pharmaceutical formulations comprising fenofibric acid and/or its salts |
-
2007
- 2007-10-12 CN CN200780045748A patent/CN101677981A/zh active Pending
- 2007-10-12 EP EP07844238A patent/EP2081563A1/en not_active Withdrawn
- 2007-10-12 ZA ZA200902488A patent/ZA200902488B/xx unknown
- 2007-10-12 AU AU2007307641A patent/AU2007307641A1/en not_active Abandoned
- 2007-10-12 KR KR1020097007466A patent/KR20090119959A/ko not_active Application Discontinuation
- 2007-10-12 EA EA200900531A patent/EA200900531A1/ru unknown
- 2007-10-12 MX MX2009003815A patent/MX2009003815A/es not_active Application Discontinuation
- 2007-10-12 CA CA002672686A patent/CA2672686A1/en not_active Abandoned
- 2007-10-12 WO PCT/US2007/081267 patent/WO2008046052A1/en active Application Filing
- 2007-10-12 SG SG2011070588A patent/SG175570A1/en unknown
- 2007-10-12 JP JP2009532610A patent/JP2010506855A/ja active Pending
-
2009
- 2009-04-13 CO CO09036680A patent/CO6160302A2/es unknown
- 2009-04-13 EC EC2009009251A patent/ECSP099251A/es unknown
- 2009-04-16 IL IL198160A patent/IL198160A0/en unknown
Also Published As
Publication number | Publication date |
---|---|
EA200900531A1 (ru) | 2009-12-30 |
KR20090119959A (ko) | 2009-11-23 |
AU2007307641A1 (en) | 2008-04-17 |
CO6160302A2 (es) | 2010-05-20 |
MX2009003815A (es) | 2009-09-07 |
CA2672686A1 (en) | 2008-04-17 |
SG175570A1 (en) | 2011-11-28 |
JP2010506855A (ja) | 2010-03-04 |
ZA200902488B (en) | 2010-10-27 |
EP2081563A1 (en) | 2009-07-29 |
IL198160A0 (en) | 2009-12-24 |
WO2008046052A1 (en) | 2008-04-17 |
CN101677981A (zh) | 2010-03-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2524320T3 (es) | Composición para la prevención o el tratamiento de enfermedad asociada con trombo o émbolo | |
CY1120888T1 (el) | Διαδερμικες φαρμακευτικες συνθεσεις περιλαμβανοντας ενεργους παραγοντες | |
ES2557303T3 (es) | Agente terapéutico para la estenosis del canal espinal | |
ES2528924T3 (es) | Formulación para el cuidado de heridas | |
PE20181177A1 (es) | Formas de dosis de liberacion controlada encerradas resistentes a manipulaciones indebidas | |
CL2009001490A1 (es) | Sistema de suministro intrauterino que comprende un progestageno o una droga con actividad progestagenica y una sustancia terapeuticamente activa seleccionada de naproxeno, indometacina, ibuprofeno, acido mefenamico o flurbiprofeno, con la capacidad de evitar o suprimir el sangrado anormal y/o irregular. | |
CR10404A (es) | Composicion farmaceutica de liberacion sostenida sobre la base de un sistema de liberacion que comprende un polimero acido-soluble y un polimero ph-dependiente | |
ECSP099251A (es) | Formulaciones farmacéuticas | |
WO2009066146A3 (en) | Stable solutions of sparingly soluble actives | |
PE20091574A1 (es) | Sistema de administracion de drogas con efecto estabilizante | |
AR072685A1 (es) | Composicion topica para el tratamiento de queratosis actinica | |
PE20141539A1 (es) | Una nueva composicion terapeutica que contiene apomorfina como principio activo | |
CO6140021A2 (es) | Composicion farmaceutica de liberacion modificada de un musculo relajante y un aine | |
NI201100119A (es) | Composición de liberación pulsatil de sildenafil y proceso para prepararla. | |
ES2563632T3 (es) | Composición de micropartículas biocompatibles de ácido algínico para la liberación controlada de principios activos por vía intravenosa | |
PE20130374A1 (es) | Composicion farmaceutica que comprende ibuprofeno | |
BR112013006632A2 (pt) | composições e sistema de liberação de distribuição de droga aprimorados | |
ES2491565T3 (es) | Agente de transfección | |
CL2012001545A1 (es) | Composiciones farmacéuticas acuosas que comprende un éster de un prostanoide, un ácido carboxílicoentre 1,2,1,6% de fosfato dibásico de sodio, cloruro de sodio, un agente de solubilización, y el resto de agua, con un ph va de 4 a 8; uso en desordenes oculares como glaucoma, retinopatia diabetica, uveitis, entre otras. | |
AR086491A1 (es) | Composicion farmaceutica que comprende fexofenadina | |
UY29637A1 (es) | Formulación de liberación prolongada de principios activos de medicamentos | |
FR2937867B1 (fr) | Association pharmaceutique contenant l acide lipoique et l acide hydroxycitrique a titre de principes actifs. | |
BRPI0608083A2 (pt) | composição compreendendo ocaperidona | |
BRPI0821975B8 (pt) | Sistema terapêutico transdérmico (tts) para liberação de substâncias ativas farmacêuticas através da pele, processo para preparação de um sistema terapêutico transdérmico e uso de uma camada polimérica contendo substância ativa | |
AR070617A1 (es) | Formulacion farmaceutica que comprende oxabispidinas/236 |